In silico prediction of inhibition of promiscuous breast cancer resistance protein (BCRP/ABCG2)

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Ding, Yi Lung ^a   Shih, Yu Hsuan ^a,d   Tsai, Fu Yuan ^b   Leong, Max K ^a,c  

^a NATIONAL DONG HWA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c Mennonite Christian Hospital   (Taiwan)

^d UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; ABC TRANSPORTER; ABCG2 PROTEIN, HUMAN; TUMOR PROTEIN;

ACCURACY; ARTICLE; COMPUTER MODEL; COMPUTER PREDICTION; CONTROLLED STUDY; PHARMACOPHORE; STRUCTURE ANALYSIS; SUPPORT VECTOR MACHINE; BREAST TUMOR; CHEMICAL STRUCTURE; COMPUTER SIMULATION; DRUG RESISTANCE; FEMALE; HUMAN; IC50; METABOLISM; PATHOLOGY; REPRODUCIBILITY; STATISTICS;

ATP-BINDING CASSETTE TRANSPORTERS; BREAST NEOPLASMS; COMPUTER SIMULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; NEOPLASM PROTEINS; REPRODUCIBILITY OF RESULTS; STATISTICS AS TOPIC; SUPPORT VECTOR MACHINE;

EID: 84897534467     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090689     Document Type: Article

References (73)

1. Klaassen CD, Aleksunes LM (2010) Xenobiotic, Bile Acid, and Cholesterol Transporters: Function and Regulation. Pharmacol Rev 62: 1-96.
2. Polgar O, Robey RW, Bates SE (2008) ABCG2: structure, function and role in drug response. Expert Opin Drug Metab Toxicol 4: 1-15.
3. Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B (2008) The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 13: 379-393.
4. Vähäkangas K, Myllynen P (2009) Drug transporters in the human blood-placental barrier. Br J Pharmacol 158: 665-678.
5. Reyes CL, Chang G (2005) Structure of the ABC Transporter MsbA in Complex with ADP?Vanadate and Lipopolysaccharide. Science 308: 1028-1031. (Pubitemid 40664414)
6. Chang G (2003) Multidrug resistance ABC transporters. FEBS Lett 555: 102-105.
7. Mao Q (2005) Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7: E118-E133.
8. Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, Dean M (1998) A Human Placenta-specific ATP-Binding Cassette Gene (ABCP) on Chromosome 4q22 That Is Involved in Multidrug Resistance. Cancer Res 58: 5337-5339. (Pubitemid 28551112)
9. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58: 931-959. (Pubitemid 32652819)
10. Hou X, Huang F, Carboni JM, Flatten K, Asmann YW, et al. (2011) Drug Efflux by Breast Cancer Resistance Protein Is a Mechanism of Resistance to the Benzimidazole Insulin-Like Growth Factor Receptor/Insulin Receptor Inhibitor, BMS-536924. Mol Cancer Ther 10: 117-125.
11. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, et al. (2011) Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance. Cancer Res 71: 3029-3041.
12. Muenster U, Grieshop B, Ickenroth K, Gnoth M (2008) Characterization of Substrates and Inhibitors for the In Vitro Assessment of Bcrp Mediated Drug-Drug Interactions. Pharm Res 25: 2320-2326.
13. Hu M, To KKW, Mak VWL, Tomlinson B (2011) The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins. Expert Opin Drug Metab Toxicol 7: 49-62.
14. Hu M, Tomlinson B (2013) Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin. Expert Opin Drug Metab Toxicol 14: 1283-1294.
15. Tomlinson B, Hu M, Lee VWY, Lui SSH, Chu TTW, et al. (2010) ABCG2 Polymorphism Is Associated With the Low-Density Lipoprotein Cholesterol Response to Rosuvastatin. Clin Pharmacol Ther 87: 558-562.
16. Declèves X, Jacob A, Yousif S, Shawahna R, Potin S, et al. (2011) Interplay of Drug Metabolizing CYP450 Enzymes and ABC Transporters in the Blood-Brain Barrier. Curr Drug Metab 12: 732-741.
17. Ciardiello F, Tortora G (2008) EGFR Antagonists in Cancer TreatmentDrug Therapy. N Engl J Med 358: 1160-1174.
18. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
19. Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF (2011) Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation. Clin Cancer Res 17: 89-99.
20. Gerstner ER, Fine RL (2007) Increased Permeability of the Blood-Brain Barrier to Chemotherapy in Metastatic Brain Tumors: Establishing a Treatment Paradigm. J Clin Oncol 25: 2306-2312.
21. El Kamar FG, Jindal K, Grossbard ML, Mizrachi HH, Kozuch PS (2004) Pancreatic carcinoma with brain metastases: case report and literature review. Dig Liver Dis 36: 355-360. (Pubitemid 41115467)
22. Oh Y, Taylor S, Bekele BN, Debnam JM, Allen PK, et al. (2009) Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 115: 2930-2938.
23. Huse JT, Holland EC (2010) Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer 10: 319-331.
24. Agarwal S, Hartz AMS, Elmquist WF, Bauer B (2011) Breast Cancer Resistance Protein and P-Glycoprotein in Brain Cancer: Two Gatekeepers Team Up. Curr Pharm Des 17: 2793-2802.
25. Schnepf R, Zolk O (2013) Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications. Expert Opin Drug Metab Toxicol 9: 287-306.
26. Lin JH, Yamazaki M (2003) Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications. Clin Pharmacokinet 42: 59-98. (Pubitemid 36092258)
27. Shukla S, Wu C-P, Ambudkar SV (2008) Development of inhibitors of ATP-binding cassette drug transporters - present status and challenges. Expert Opin Drug Metab Toxicol 4: 205-223. (Pubitemid 351308418)
28. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234. (Pubitemid 43336035)
29. Poguntke M, Hazai E, Fromm MF, Zolk O (2010) Drug transport by breast cancer resistance protein. Expert Opin Drug Metab Toxicol 6: 1363-1384.
30. Lagorce D, Reynes C, Camproux A-C, Miteva MA, Sperandio O, et al. (2011) In Silico ADME/Tox Predictions. In: Tsaioun K, Kates SA, editors. ADMET for Medicinal Chemists: A Practical Guide. Hoboken, New Jersey: John Wiley & Sons, Inc. pp. 29-124.
31. Chang C, Ekins S, Bahadduri P, Swaan PW (2006) Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev 58: 1431-1450. (Pubitemid 44794430)
32. Cramer J, Kopp S, Bates SE, Chiba P, Ecker GF (2007) Multispecificity of Drug Transporters: Probing Inhibitor Selectivity for the Human Drug Efflux Transporters ABCB1 and ABCG2. ChemMedChem 2: 1783-1788.
33. Matsson P, Englund G, Ahlin G, Bergström CAS, Norinder U, et al. (2007) A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2). J Pharmacol Exp Ther 323: 19-30. (Pubitemid 47443263)
34. Sim HM, Loh KY, Yeo WK, Lee CY, Go ML (2011) Aurones as Modulators of ABCG2 and ABCB1: Synthesis and Structure-Activity Relationships. ChemMedChem 6: 713-724.
35. Gandhi Y, Morris M (2009) Structure-Activity Relationships and Quantitative Structure-Activity Relationships for Breast Cancer Resistance Protein (ABCG2). AAPS J 11: 541-552.
36. Ishikawa T, Hirano H, Saito H, Sano K, Ikegami Y, et al. (2012) Quantitative Structure-Activity Relationship (QSAR) Analysis to Predict Drug-Drug Interactions of ABC Transporter ABCG2. Mini Rev Med Chem 12: 505-514.
37. Wei Y, Ma Y, Zhao Q, Ren Z, Li Y, et al. (2012) New Use for an Old Drug: Inhibiting ABCG2 with Sorafenib. Mol Cancer Ther 11: 1693-1702.
38. Pan Y, Chothe PP, Swaan PW (2013) Identification of Novel BCRP Inhibitors by Virtual Screening. Mol Pharmaceutics 10: 1236-1248.
39. Sim H-M, Lee C-Y, Ee PLR, Go M-L (2008) Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). Eur J Pharm Sci 35: 293-306.
40. Nicolle E, Boumendjel A, Macalou S, Genoux E, Ahmed-Belkacem A, et al. (2009) QSAR analysis and molecular modeling of ABCG2-specific inhibitors. Adv Drug Deliv Rev 1: 34-46.
41. Tan KP, Wang B, Yang M, Boutros PC, MacAulay J, et al. (2010) Aryl Hydrocarbon Receptor Is a Transcriptional Activator of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). Mol Pharmacol 78: 175-185.
42. Ecker GF, Stockner T, Chiba P (2008) Computational models for prediction of interactions with ABC-transporters. Drug Discov Today 13: 311-317.
43. Leong MK (2007) A Novel Approach Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) for Prediction of hERG Liability. Chem Res Toxicol 20: 217-226.
44. Lexa KW, Carlson HA (2012) Protein flexibility in docking and surface mapping. Q Rev Biophys 45: 301-343.
45. Leong MK, Chen T-H (2008) Prediction of Cytochrome P450 2B6-Substrate Interactions Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) Approach Med Chem 4: 396-406.
46. Leong MK, Chen Y-M, Chen H-B, Chen P-H (2009) Development of a New Predictive Model for Interactions with Human Cytochrome P450 2A6 Using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) Approach. Pharm Res 26: 987-1000.
47. Chen C-N, Shih Y-H, Ding Y-L, Leong MK (2011) Predicting Activation of the Promiscuous Human Pregnane X Receptor by Pharmacophore Ensemble/Support Vector Machine Approach. Chem Res Toxicol 24: 1765-1778.
48. Leong MK, Chen H-B, Shih Y-H (2012) Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme. PLoS One 7: e33829.
49. Pick A, Müller H, Mayer R, Haenisch B, Pajeva IK, et al. (2011) Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem 19: 2090-2102.
50. Pick A, Müller H, Wiese M (2008) Structure-activity relationships of new inhibitors of breast cancer resistance protein (ABCG2). Bioorg Med Chem 16: 8224-8236.
51. Pick A, Müller H, Wiese M (2009) Novel lead for potent inhibitors of breast cancer resistance protein (BCRP). Bioorg Med Chem Lett 20: 180-183.
52. Juvale K, Pape VFS, Wiese M (2012) Investigation of chalcones and benzochalcones as inhibitors of breast cancer resistance protein. Bioorg Med Chem 20: 346-355.
53. Juvale K, Wiese M (2012) 4-Substituted-2-phenylquinazolines as inhibitors of BCRP. Bioorg Med Chem Lett 22: 6766-6769.
54. Chang G, Guida WC, Still CW (1989) An internal-coordinate Monte Carlo method for searching conformational space. J Am Chem Soc 111: 4379-4386.
55. Kolossváry I, Guida WC (1996) Low Mode Search. An Efficient, Automated Computational Method for Conformational Analysis: Application to Cyclic and Acyclic Alkanes and Cyclic Peptides. J Am Chem Soc 118: 5011-5019. (Pubitemid 26200976)
56. Still WC, Tempczyk A, Hawley RC, Hendrickson T (1990) Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 112: 6127-6129.
57. Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17: 490-519.
58. Li H, Sutter J, Hoffmann R (2000) HypoGen: An Automated System for Generating 3D Predictive Pharmacophore Models. In: Güner OF, editor. Pharmacophore Perception, Development, and Use in Drug Design. La Jolla, California: International University Line. pp. 171-189.
59. Evans DA, Doman TN, Thorner DA, Bodkin MJ (2007) 3D QSAR methods: Phase and Catalyst compared. J Chem Inf Model 47: 1248-1257. (Pubitemid 46973738)
60. Leong MK, Lin S-W, Chen H-B, Tsai F-Y (2010) Predicting Mutagenicity of Aromatic Amines by Various Machine Learning Approaches. Toxicol Sci 116: 498-513.
61. Consonni V, Ballabio D, Todeschini R (2010) Evaluation of model predictive ability by external validation techniques. J Chemometr 24: 194-201.
62. Breiman L, Spector P (1992) Submodel Selection and Evaluation in Regression: The X-Random Case. Int Statist Rev 60: 291-319.
63. Roy K, Mitra I, Kar S, Ojha PK, Das RN, et al. (2012) Comparative Studies on Some Metrics for External Validation of QSPR Models. J Chem Inf Model 52: 396-408.
64. Golbraikh A, Shen M, Xiao Z, Xiao Y-D, Lee K-H, et al. (2003) Rational selection of training and test sets for the development of validated QSAR models. J Comput-Aided Mol Des 17: 241-253. (Pubitemid 37062785)
65. Schüürmann G, Ebert R-U, Chen J, Wang B, Kühne R (2008) External Validation and Prediction Employing the Predictive Squared Correlation Coefficient-Test Set Activity Mean vs Training Set Activity Mean. J Chem Inf Model 48: 2140-2145.
66. Chirico N, Gramatica P (2012) Real External Predictivity of QSAR Models. Part 2. New Intercomparable Thresholds for Different Validation Criteria and the Need for Scatter Plot Inspection. J Chem Inf Model 52: 2044-2058.
67. 2 metrics for validation of QSPR models. Chemometrics Intell Lab Syst 107: 194-205.
68. Casalegno M, Sello G, Benfenati E (2008) Definition and Detection of Outliers in Chemical Space. J Chem Inf Model 48: 1592-1601.
69. Reymond J-L, van Deursen R, Blum LC, Ruddigkeit L (2010) Chemical space as a source for new drugs. MedChemComm 1: 30-38.
70. Gnanadesikan R, Kettenring JR (1972) Robust estimates, residuals, and outlier detection with multiresponse data. Biometrics 28: 81-124.
71. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, et al. (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-245. (Pubitemid 47072063)
72. Gupta A, Zhang Y, Unadkat JD, Mao Q (2004) HIV Protease Inhibitors Are Inhibitors but Not Substrates of the Human Breast Cancer Resistance Protein (BCRP/ABCG2). J Pharmacol Exp Ther 310: 334-341. (Pubitemid 38812728)
73. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, et al. (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292: 2329-2333. (Pubitemid 32568055)